72 related articles for article (PubMed ID: 1673593)
1. Effects of a histamine type-2 receptor antagonist (BMY-25368) on gastric secretion in horses.
Orsini JA; Dreyfuss DJ; Vecchione J; Spencer PA; Uhlman R
Am J Vet Res; 1991 Jan; 52(1):108-10. PubMed ID: 1673593
[TBL] [Abstract][Full Text] [Related]
2. Effects of a histamine type 2 receptor antagonist, BMY-26539-01, on equine gastric acid secretion.
Orsini JA; Spencer PA
Can J Vet Res; 2001 Jan; 65(1):55-9. PubMed ID: 11227196
[TBL] [Abstract][Full Text] [Related]
3. Histamine-induced gastric acid secretion in horses.
Kitchen DL; Merritt AM; Burrow JA
Am J Vet Res; 1998 Oct; 59(10):1303-6. PubMed ID: 9781466
[TBL] [Abstract][Full Text] [Related]
4. Effect of the novel histamine H2-antagonist 5,6-dimethyl-2-[4-[3-(1- piperidinomethyl)phenoxy]-(z)-2-butenylamino]-4(1H)-pyrimidine dihydrochloride on histamine-induced gastric acid secretion in Heidenhain pouch dogs.
Uchida M; Ohba S; Ikarashi Y; Misaki N; Kawano O
Arzneimittelforschung; 1993 Aug; 43(8):873-6. PubMed ID: 8105784
[TBL] [Abstract][Full Text] [Related]
5. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[TBL] [Abstract][Full Text] [Related]
6. Effects of the new H2-receptor antagonist 3-amino-4-[4- [4- (1-piperidinomethyl)-2-pyridyloxy]-cis-2-butenylamino]-3-cyclobutene-1, 2- dione hydrochloride on gastric acid secretion and ulceration.
Muramatsu M; Isobe Y; Arai I; Hirose-Kijima H; Usuki-Ito C; Nagai H; Aihara H; Otomo S
Arzneimittelforschung; 1990 Jan; 40(1):49-54. PubMed ID: 1971169
[TBL] [Abstract][Full Text] [Related]
7. Chronic administration of H2-antagonists does not alter gastric secretory responses to histamine, or the antisecretory activity of sufotidine.
Stables R; Humphray JM; Reeves JJ
Aliment Pharmacol Ther; 1990; 4 Suppl 1():7-13. PubMed ID: 1983348
[TBL] [Abstract][Full Text] [Related]
8. Effect of BMY-25368, a potent and long-acting histamine H2-receptor antagonist, on gastric secretion and aspirin-induced gastric lesions in the dog.
Cavanagh RL; Buyniski JP
Aliment Pharmacol Ther; 1989 Jun; 3(3):299-313. PubMed ID: 2577694
[TBL] [Abstract][Full Text] [Related]
9. Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs.
Lin TM; Evans DC; Warrick MW; Pioch RP
J Pharmacol Exp Ther; 1986 Nov; 239(2):406-10. PubMed ID: 2877081
[TBL] [Abstract][Full Text] [Related]
10. Prevention of aspirin-induced gastric mucosal injury by histamine H2 receptor antagonists: a crossover endoscopic and intragastric pH study in the dog.
Cavanagh RL; Buyniski JP; Schwartz SE
J Pharmacol Exp Ther; 1987 Dec; 243(3):1179-84. PubMed ID: 2891837
[TBL] [Abstract][Full Text] [Related]
11. Dose-response curve analysis of gastric secretory responses in the dog and man to impromidine: a new histamine-H2-receptor agonist.
McIsaac RL; Johnston BJ; Flannery MC
J Pharmacol Exp Ther; 1983 Apr; 225(1):186-90. PubMed ID: 6131998
[TBL] [Abstract][Full Text] [Related]
12. The effect of the H2-antagonist niperotidine on intragastric acidity in healthy subjects undergoing 24-hour pH-monitoring.
Palasciano G; Maggi V; Portincasa P
Ital J Gastroenterol; 1990 Oct; 22(5):291-4. PubMed ID: 1983712
[TBL] [Abstract][Full Text] [Related]
13. Antisecretory effects of two new histamine H2-receptor antagonists.
Bickel M; Herling AW; Rising TJ; Wirth K
Arzneimittelforschung; 1986 Sep; 36(9):1358-63. PubMed ID: 2878669
[TBL] [Abstract][Full Text] [Related]
14. Antisecretory and antilesional effect of a new histamine H2-receptor antagonist, IT-066, in rats.
Isobe Y; Nagai H; Muramatsu M; Aihara H; Otomo S
J Pharmacol Exp Ther; 1990 Dec; 255(3):1078-82. PubMed ID: 1979811
[TBL] [Abstract][Full Text] [Related]
15. The new histamine H2-receptor antagonist ranitidine. Duration of action.
Dammann HG; Simon B
Scand J Gastroenterol Suppl; 1981 Jun; 69():39-43. PubMed ID: 6119781
[TBL] [Abstract][Full Text] [Related]
16. Kinetics and duration of action of ranitidine on gastric secretion and its effect on pancreatic secretion in duodenal ulcer patients.
Konturek SJ; Obtułowicz W; Kwiecień N; Kopp B; Oleksy J
Scand J Gastroenterol Suppl; 1981 Jun; 69():91-9. PubMed ID: 6119789
[TBL] [Abstract][Full Text] [Related]
17. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
Dammann HG; Gottlieb WR; Walter TA; Dreyer M; Müller P; Simon B; Keohane P
Hepatogastroenterology; 1986 Oct; 33(5):217-20. PubMed ID: 2879782
[TBL] [Abstract][Full Text] [Related]
18. [Gastric acid secretion and histamine H2 receptor antagonists].
Gespach C; Emami S; Di Gioia Y; Chastre E
Gastroenterol Clin Biol; 1990; 14(12):982-94. PubMed ID: 1981198
[No Abstract] [Full Text] [Related]
19. A review of the animal pharmacology of ranitidine--a new, selective histamine H2-antagonist.
Brittain RT; Daly MJ
Scand J Gastroenterol Suppl; 1981 Jun; 69():1-9. PubMed ID: 6119770
[TBL] [Abstract][Full Text] [Related]
20. A comparison of some of the pharmacological properties of etintidine, a new histamine H2-receptor antagonist, with those of cimetidine, ranitidine and tiotidine.
Cavanagh RL; Usakewicz JJ; Buyniski JP
J Pharmacol Exp Ther; 1983 Jan; 224(1):171-9. PubMed ID: 6129316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
